A detailed history of Morgan Stanley transactions in Hille Vax, Inc. stock. As of the latest transaction made, Morgan Stanley holds 251,568 shares of HLVX stock, worth $467,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares
251,568
Previous 58,172 332.46%
Holding current value
$467,916
Previous $841,000 47.44%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.58 - $14.42 $305,565 - $2.79 Million
193,396 Added 332.46%
251,568 $442,000
Q2 2024

Oct 17, 2024

SELL
$11.86 - $15.93 $57,651 - $77,435
-4,861 Reduced 7.71%
58,172 $841,000
Q2 2024

Aug 14, 2024

SELL
$11.86 - $15.93 $57,651 - $77,435
-4,861 Reduced 7.71%
58,172 $841,000
Q1 2024

Oct 17, 2024

BUY
$14.15 - $19.75 $68,783 - $96,004
4,861 Added 8.36%
63,033 $1.05 Million
Q1 2024

Aug 16, 2024

SELL
$14.15 - $19.75 $5.55 Million - $7.74 Million
-391,972 Reduced 86.15%
63,033 $1.05 Million
Q1 2024

May 15, 2024

SELL
$14.15 - $19.75 $5.55 Million - $7.74 Million
-391,972 Reduced 86.15%
63,033 $1.05 Million
Q4 2023

Aug 16, 2024

BUY
$10.35 - $17.11 $4.11 Million - $6.79 Million
396,833 Added 682.17%
455,005 $7.3 Million
Q4 2023

Feb 13, 2024

SELL
$10.35 - $17.11 $1.65 Million - $2.72 Million
-159,066 Reduced 25.9%
455,005 $7.3 Million
Q3 2023

Nov 15, 2023

BUY
$11.59 - $16.7 $254,296 - $366,414
21,941 Added 3.71%
614,071 $8.26 Million
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.76 $43,237 - $62,733
-3,344 Reduced 0.56%
592,130 $10.2 Million
Q1 2023

May 15, 2023

SELL
$14.73 - $18.18 $144,928 - $178,873
-9,839 Reduced 1.63%
595,474 $9.84 Million
Q4 2022

Feb 14, 2023

BUY
$13.52 - $21.46 $6.79 Million - $10.8 Million
502,197 Added 487.02%
605,313 $10.1 Million
Q3 2022

Nov 14, 2022

SELL
$10.5 - $22.01 $10,353 - $21,701
-986 Reduced 0.95%
103,116 $1.76 Million
Q2 2022

Aug 15, 2022

BUY
$8.7 - $20.18 $905,687 - $2.1 Million
104,102 New
104,102 $1.14 Million

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $62.2M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.